Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03210714
Title Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

pediatric ependymoma

Advanced Solid Tumor

neuroblastoma

pediatric osteosarcoma

hepatoblastoma

rhabdomyosarcoma

histiocytosis

neuroectodermal tumor

Ewing sarcoma

non-Hodgkin lymphoma

high grade glioma

childhood medulloblastoma

sarcoma

Therapies

Erdafitinib

Age Groups: adult | child
Covered Countries USA

Additional content available in CKB BOOST